Drug Profile
MIV 711
Alternative Names: MIV-711Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Medivir AB
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Osteoporosis therapies; Small molecules
- Mechanism of Action Cathepsin K inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Osteoarthritis
Highest Development Phases
- Phase II Osteoarthritis
- Discontinued Bone metastases; Osteoporosis
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Osteoarthritis(In volunteers) in USA (PO, Tablet)
- 28 Feb 2021 No recent reports of development identified for phase-I development in Osteoarthritis(In volunteers) in USA (PO, Capsule)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Osteoarthritis(In volunteers) in Sweden (PO, Capsule)